Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males-Reference-Cited by-同舟云学术

Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males

Published:2019-11-22 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Bergman Hanna¹,Buckley Brian S¹²,Villanueva Gemma¹,Petkovic Jennifer¹³,Garritty Chantelle¹⁴,Lutje Vittoria⁵,Riveros-Balta Alina Ximena⁶,Low Nicola⁷,Henschke Nicholas¹

Affiliation:

1. Cochrane; Cochrane Response; St Albans House 57-59 Haymarket London UK SW1Y 4QX

2. University of Phillipines; Department of Surgery; Manila Philippines

3. University of Ottawa; Bruyère Research Institute; 43 Bruyère St Annex E, room 312 Ottawa ON Canada K1N 5C8

4. Ottawa Hospital Research Institute; Ottawa Methods Centre, Clinical Epidemiology Program; Ottawa Ontario Canada K1H 8L1

5. Liverpool School of Tropical Medicine; Department of Clinical Sciences; Pembroke Place Liverpool UK L3 5QA

6. World Health Organization; Initiative for Vaccine Research; Geneva Switzerland

7. University of Bern; Institute of Social and Preventive Medicine (ISPM); Finkenhubelweg 11 Bern Switzerland CH-3012

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013479/epdf/full

Reference170 articles.

1. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo controlled study;Denny;Vaccine,2013

2. GSK 107863 (HPV-020 PRI) Evaluation of the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine 580299 (Cervarix TM) in adult human immunodeficiency virus (HIV) infected female subjects www.gsk-clinicalstudyregister.com/files2/gsk-107863-clinical-study-report2-redact.pdf

3. GlaxoSmithKline Evaluation of the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV vaccine 580299 (Cervarix TM) in adult human immunodeficiency virus (HIV) infected female subjects clinicaltrials.gov/ct2/show/results/NCT00586339

4. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial;Dobson;JAMA,2013

5. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial;Krajden;Clinical and Vaccine Immunology,2011

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of HPV vaccine as part of national immunization program for preventing HPV infection in Thai schoolgirls after seven years post-vaccination;Human Vaccines & Immunotherapeutics;2024-09-06

2. Vaccines and Vaccine Response in the Small Bowel Transplant Patient;Gastroenterology Clinics of North America;2024-09

3. The most common forms of cancer and oncogenic papillomaviruses;Advances in Molecular Oncology;2024-06-28

4. Human papillomavirus infection and the risk of cancer at specific sites other than anogenital tract and oropharyngeal region: an umbrella review;eBioMedicine;2024-06

5. The Role and Development of Peptide Vaccines in Cervical Cancer Treatment;International Journal of Peptide Research and Therapeutics;2024-05-24